Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stuck In Reverse: Another Start-up Takes Reverse Merger Route To Public Markets

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal results in unlikely combination of antbiotics maker Replidyne and device firm Cardiovascular Systems.

You may also be interested in...



Deerfield To NitroMed: Not So Fast, Not So Cheap

NitroMed stakeholder Deerfield Management moves to block the company’s planned reverse merger with Archemix with a $0.50 per share bid of its own.

Deerfield To NitroMed: Not So Fast, Not So Cheap

NitroMed stakeholder Deerfield Management moves to block the company’s planned reverse merger with Archemix with a $0.50 per share bid of its own.

Nitromed Reverse Merger Is Quickest Way To Cash For Archemix

Nitromed’s status as essentially a publicly-traded cash shell, with the sell-off of BiDil, made it an attractive partner.

Related Content

Topics

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel